Medical Crossfire®: Perfecting The Diagnosis And Treatment Of EGPA: Patient Perspectives And Expert Insight

Released On
August 18, 2020

Expires On
August 18, 2021

Media Type

Completion Time
90 minutes

Allergy & Immunology, Pharmacy, Primary Care, Pulmonology, Rheumatology

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from GlaxoSmithKline.

Credit Available

  • Physicians — maximum of 1.50 AMA PRA Category 1 Credit(s)
  • Nurses — maximum of 1.50 Contact Hour

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational program is directed toward all pulmonologists, primary care physicians, rheumatologists, nurse practitioners, physician assistants, and other health care professionals who treat EGPA.

Program Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) and important aspects of clinical presentation. The nuances of diagnosis, current and emerging treatments, and coordination of a multidisciplinary care team is presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Evaluate recommendations for early assessment and diagnosis for patients with EGPA
  • Discuss relevant patient insights and strategies to improve the collaborative care approach
  • Assess disease progression to properly screen and diagnose EGPA and develop an individualized management plan


Michael E. Wechsler, MD, MMSc

Michael E. Wechsler, MD, MMSc

Professor of Medicine
Director, The Cohen Family Asthma Institute
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Health
Denver, CO

Praveen Akuthota, MD

Praveen Akuthota, MD

Associate Clinical Professor of Medicine
University of California, San Diego
La Jolla, CA

Anisha Dua, MD, MPH

Anisha Dua, MD, MPH

Associate Professor of Medicine (Rheumatology)
Rheumatology Fellowship Program Director
Director, Vasculitis Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Rula A. Hajj-Ali, MD, FACP

Rula A. Hajj-Ali, MD, FACP

Professor of Medicine
Associate Director
Center for Vasculitis Care and Research
Cleveland Clinic
Cleveland, OH

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hours.

Disclosures of Conflicts of Interest

Michael E. Wechsler, MD, MMSc

  • Grant Research Support: : AstraZeneca, Regeneron, Sanofi, Teva;
  • Consultant: AstraZeneca, Equillium, Genentech, Sanofi Genzyme, GlaxoSmithKline, Novartis, Regeneron, resTORbio, Sanofi

Praveen Akuthota, MD

  • Grant Research Support: AstraZeneca, GlaxoSmithKline; Consultant: AstraZeneca, GlaxoSmithKline

Anisha Dua, MD, MPH

  • Consultant: ChemoCentryx, GlaxoSmithKline

Rula A. Hajj-Ali, MD, FACP

  • Speakers Bureau: AbbVie, Rockpointe Corporation

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Video” will be available for your reference.
  • In order to receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.
Certificates will be emailed to the participant


Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.